KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Net Income (2016 - 2025)

Historic Net Income for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Net Income rose 558.33% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 3263.14%. This contributed to the annual value of -$119.0 million for FY2024, which is 5689.72% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Net Income of -$35.0 million as of Q3 2025, which was up 558.33% from -$39.2 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Net Income peaked at $7.2 million during Q4 2024, and registered a low of -$159.1 million during Q2 2022.
  • Moreover, its 5-year median value for Net Income was -$52.4 million (2024), whereas its average is -$74.5 million.
  • Per our database at Business Quant, Nektar Therapeutics' Net Income tumbled by 5689.88% in 2021 and then surged by 11719.15% in 2024.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Net Income stood at -$146.9 million in 2021, then soared by 54.66% to -$66.6 million in 2022, then skyrocketed by 36.82% to -$42.1 million in 2023, then soared by 117.19% to $7.2 million in 2024, then plummeted by 583.66% to -$35.0 million in 2025.
  • Its Net Income was -$35.0 million in Q3 2025, compared to -$39.2 million in Q2 2025 and -$46.4 million in Q1 2025.